VCM
MDGL icon

Versant Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Versant Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.51K Buy
+3
New +$1.58K ﹤0.01% 2649
2025
Q2 		– Sell
-3
Closed -$994 – 2694
2025
Q1 		$994 Buy
+3
New +$986 ﹤0.01% 2359
2023
Q3 		– Sell
-2
Closed -$462 – 2007
2023
Q2 		$462 Buy
+2
New +$542 ﹤0.01% 1854

Other funds holding MDGL

FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
EB
Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return
CI
CX Institutional Auburn, Indiana $3.69B AUM 15.82% 1-Year Est. Return

Versant Capital Management's MDGL Position: Q3 2026 in Review

Versant Capital Management opened a new position in Madrigal Pharmaceuticals (MDGL) in Q3 2026: 3 shares worth $1.51K. The stake represents ﹤0.01% of the portfolio and ranks #2649 among its holdings. This is a return to the name: Versant Capital Management previously reported a position in MDGL as recently as Q1 2025.

Versant Capital Management first reported a position in MDGL in Q2 2023 and has held it in 3 quarters since. 8 funds tracked by Wall St. Rank hold MDGL as of Q3 2026.

  • Versant Capital Management held 3 shares of Madrigal Pharmaceuticals worth $1.51K as of Q3 2026.
  • Madrigal Pharmaceuticals was a new Versant Capital Management position in Q3 2026.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #2649 holding.
  • Versant Capital Management first reported a position in Madrigal Pharmaceuticals in Q2 2023 and has held it in 3 quarters since.
  • 8 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.